Last updated: October 2026

WVE-003 is an investigational allele-selective treatment candidate from Wave Life Sciences, designed to target the mutant huntingtin gene while preserving the healthy copy.

Current status

It remains in early clinical development, and additional trials and data will be needed before any regulatory decision. It is not FDA approved, and timing, eligibility, safety, effectiveness, availability, and cost remain uncertain.

For the newest coverage across the HD treatment pipeline, visit What’s Happening in HD Treatment.